David Krisky
Overview
Explore the profile of David Krisky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ling A, Solomon I, Landivar A, Nakashima H, Woods J, Santos A, et al.
Nature
. 2023 Oct;
623(7985):157-166.
PMID: 37853118
Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM). Here we report the results of a first-in-human phase...
2.
Goss J, Krisky D, Wechuck J, Wolfe D
J Pain Res
. 2014 Jan;
7:71-9.
PMID: 24470772
Chronic pain represents a major medical burden not only in terms of suffering but also in terms of economic costs. Traditional medical approaches have so far proven insufficient in treating...
3.
Ludvigsson J, Krisky D, Casas R, Battelino T, Castano L, Greening J, et al.
N Engl J Med
. 2012 Feb;
366(5):433-42.
PMID: 22296077
Background: The 65-kD isoform of glutamic acid decarboxylase (GAD65) is a major autoantigen in type 1 diabetes. We hypothesized that alum-formulated GAD65 (GAD-alum) can preserve beta-cell function in patients with...
4.
Fink D, Wechuck J, Mata M, Glorioso J, Goss J, Krisky D, et al.
Ann Neurol
. 2011 Jul;
70(2):207-12.
PMID: 21796661
Objective: Preclinical evidence indicates that gene transfer to the dorsal root ganglion using replication-defective herpes simplex virus (HSV)-based vectors can reduce pain-related behavior in animal models of pain. This clinical...
5.
Wolfe D, Wechuck J, Krisky D, Mata M, Fink D
Pain Med
. 2009 Oct;
10(7):1325-30.
PMID: 19818042
The first human trial of gene therapy for chronic pain, a phase 1 study of a nonreplicating herpes simplex virus (HSV)-based vector engineered to express preproenkephalin in patients with intractable...
6.
Goins W, Marconi P, Krisky D, Wolfe D, Glorioso J, Ramakrishnan R, et al.
Curr Protoc Hum Genet
. 2008 Apr;
Chapter 12:Unit 12.11.
PMID: 18428322
Advances in identification and characterization of gene products responsible for specific diseases of the nervous system have opened opportunities for novel therapies using gene transfer vectors for gene replacement. Herpes...
7.
Srinivasan R, Huang S, Chaudhry S, Sculptoreanu A, Krisky D, Cascio M, et al.
Nat Methods
. 2007 Aug;
4(9):733-9.
PMID: 17676048
Pathological alterations of ion channel activity result from changes in modulatory mechanisms governing receptor biology. Here we describe a conditional herpes simplex virus (HSV) replication-based strategy to discover channel modulators...
8.
Puskovic V, Wolfe D, Wechuck J, Krisky D, Collins J, Glorioso J, et al.
Mol Ther
. 2006 Sep;
14(5):710-5.
PMID: 16949343
To investigate the neuroprotective effects of erythropoietin (EPO) in a rodent model of Parkinson disease, we inoculated a nonreplicating herpes simplex virus-based vector expressing EPO (vector DHEPO) into the striatum...
9.
Jiang C, Ataai M, Ozuer A, Krisky D, Wechuck J, Pornsuwan S, et al.
Biotechnol Bioeng
. 2006 May;
95(1):48-57.
PMID: 16673413
Metal catalyzed oxidation (MCO), which typically involves oxygen free radical generation, is an important pathway that leads to the deterioration of many biological molecules in solution. The occurrence of MCO...